Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.55 |
| ▸ | MMP13 | P45452 | 6/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8361646 | 0.91 | MMP2 (0.51) | MMP2MMP13MCHR1SMN1; SMN2KMT2A | |
| SCHEMBL6605195 | 0.91 | MMP2 (0.51) | MMP2MMP13MCHR1SMN1; SMN2GAA | |
| SCHEMBL6572436 | 0.88 | MMP2 (0.53) | MMP2MMP13MCHR1SMN1; SMN2GAA | |
| SCHEMBL5898986 | 0.87 | MMP13 (0.69) | MMP2MMP13SMN1; SMN2GAAKMT2A | |
| SCHEMBL8361686 | 0.87 | MMP2 (0.47) | MMP2MMP13MCHR1SMN1; SMN2GAA | |
| SCHEMBL5898944 | 0.86 | MMP2 (0.54) | MMP2MMP13SMN1; SMN2KMT2AMAPT | |
| SCHEMBL5898993 | 0.85 | MMP2 (0.49) | MMP2MMP13SMN1; SMN2KMT2AMAPT | |
| SCHEMBL5898978 | 0.85 | MMP13 (0.60) | MMP2MMP13SMN1; SMN2GAAKMT2A | |
| SCHEMBL8361679 | 0.85 | MMP13 (0.64) | MMP2MMP13MCHR1SMN1; SMN2KMT2A | |
| SCHEMBL5898961 | 0.82 | MMP2 (0.52) | MMP2MMP13SMN1; SMN2KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115632-B1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| US-6696449-B2 | CONTROL DEGRADATION OF CONENCTING TISSUE; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | PHARMACIA CORPORATION | 2003-09-11 | — | — | US | disclosed |
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | ARSA, MMP1, MMP3 | MMP2 7/4885MMP13 8/4885MCHR1 2768/4885 |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | ARSA, AADAC, ASPH | MMP2 27/4885MMP13 26/4885MCHR1 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.